General Information
Revision date
2017-06-22
Product name
Repaglinide and Metformin Hydrochloride Tablets
Manufacturer Name
Lupin Limited
Icons in SDS
Company Information
company name
Lupin Limited
Section 2
SECTION 2: Hazards identification
Fire and Explosion Expected to be non-combustible. Health Repaglinide and metformin hydrochloride tablets are contraindicated in: Severe renal impairment (GFR below 30 mL/min. 1.73 m2) Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin Patients receiving gemfibrozil Patients with known hypersensitivity to repaglinide, metformin HCl or any inactive ingredients in repaglinide and metformin hydrochloride tablets
Environmental hazards
No information is available about the potential of this product to produce adverse environmental effects.
